CORRECTION article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1641150
Correction: Efficacy and Safety of Pegylated Interferon in the Treatment of JAK2 V617F -Positive Polycythemia Vera with a Dose De-escalation Strategy: A Single-Center Retrospective Study
Provisionally accepted
- Peking Union Medical College Hospital, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
In the published article, there was an error in the Funding statement. The funder National High Level Hospital Clinical Research Funding 2022-PUMCH-B-047 to Ming-hui Duan was erroneously omitted. The correct Funding statement appears below.FUNDINGThis study was supported by the National High Level Hospital Clinical Research Funding 2022-PUMCH-B-047 to Ming-hui Duan. This study also received funding from Xiamen Amoytop Biotech Co.,Ltd. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: Polycythemia Vera, Pegylated interferon, JAK2v617F mutation, Dose De-Escalation Strategy, Hematological and Molecular Response
Received: 04 Jun 2025; Accepted: 06 Jun 2025.
Copyright: © 2025 Chang, Li, Cai, Li and Duan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Minghui Duan, Peking Union Medical College Hospital, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.